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ABSTRACT
Endothelial monocyte-activating polypeptide-II (EMAP II) is an
antiangiogenic factor for rapidly growing endothelial cells that is
released from tumor cells under physiological stress such as
hypoxia. We have previously shown that the interaction be-
tween EMAP II and the -subunit of ATP synthase, -ATP
synthase, can play a regulatory function in the growth of endo-
thelial cells. In the current study, we found that EMAP II--ATP
synthase interaction could be inhibited by excess heparin,
whereas the interaction could be enhanced by a low concen-
tration of heparin. Both EMAP II and -ATP synthase could
specifically interact with heparin, and this interaction was in-
creased under acidic conditions. In addition, EMAP II and
-ATP synthase were found to contain the heparin binding
motifs determined by analysis using site-directed mutant
forms. In endothelial cells, binding of EMAP II to cells was
dramatically enhanced, and -ATP synthase could associate
with heparan sulfate at acidic pH. The inhibitory effect of EMAP
II on the growth of cultured endothelial cells was also signifi-
cantly enhanced at acidic pH. Analysis using mutant EMAP II
proteins demonstrated that heparan sulfate was essential for
the enhanced binding and EMAP II function to endothelial cells
at acidic pH. Furthermore, the enhanced inhibitory effects of
EMAP II could be abrogated by excess heparin or heparinase
treatment. In the endothelial cell, heparan sulfate may regulate
the function of EMAP II released from the tumor cell in hypoxic
condition.
Endothelial monocyte-activating polypeptide-II (EMAP II)
is a novel molecule first identified from cell growth medium
conditioned by murine methylcholanthrene A-induced fibro-
sarcoma cells, with pleiotropic activities toward endothelial
cells (ECs), monocytes/macrophages, and neutrophils (Kao et
al., 1992, 1994a,b). EMAP II is structurally and functionally
identical to the C-terminal domain of p43 that is associated
with the mammalian multisynthase tRNA synthase complex
(Quevillon et al., 1997; Ko et al., 2001; Shalak et al., 2001). It
has been shown that EMAP II is released from the cells not
only undergoing apoptosis (Knies et al., 1998) but also in
response to cellular stress such as exposure to hypoxia or
treatment with certain chemotherapeutic agents (Barnett et
al., 2000; Matschurat et al., 2003). EMAP II induces a pro-
coagulant activity on the surface of ECs, increases expression
of tumor necrosis factor-receptor 1 (Berger et al., 2000b), and
is chemotactic for neutrophils and monocytes, suggesting
that EMAP II is a proinflammatory cytokine (Kao et al.,
1994a). More recently, EMAP II has been shown to induce
lymphocyte apoptosis after secretion from colorectal cancer
cells without any stimuli (Murray et al., 2004).
EMAP II also has an antiangiogenic property that targets
rapidly growing vascular beds (Berger et al., 2000a). EMAP
II induces proliferation inhibition and apoptosis of growing
cultured capillary endothelium, which is magnified by con-
comitant hypoxia (Schwarz et al., 1999). Our previous report
showed that EMAP II binds with the  subunit of ATP
synthase, -ATP synthase, on the surface of ECs and that the
interaction between EMAP II and -ATP synthase can play a
regulatory function in the growth of ECs (Chang et al., 2002).
In general, ATP synthase is present in the inner membrane
of mitochondria and plays an important role in energy me-
tabolism by synthesizing ATP (Stock et al., 2000). Recent
reports suggested that ATP synthase was also expressed in
the plasma membrane and that ectopic ATP synthase func-
tions in an unexpected manner. For example, cell surface
ATP synthase is a cellular receptor for high-density lipopro-
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tein in hepatocytes (Martinez et al., 2003). In addition, ATP
synthase in the surface of ECs is a cellular receptor for
angiostatin (Moser et al., 1999) as well as EMAP II (Chang et
al., 2002).
Tumor tissues have been shown to be hypoxic and acidic
(Tannock, 1972). Nevertheless, ECs in tumor tissues survive
fairly well under these conditions (Burbridge et al., 1999). In
fact, hypoxia is one of the major signals that induce angio-
genesis. Fibroblast growth factor (FGF)-2 and vascular en-
dothelial growth factor (VEGF) are the major regulators of
angiogenesis (Veikkola et al., 2000). In addition, it has been
shown that EMAP II can be secreted from tumor cells under
hypoxic conditions (Barnett et al., 2000), suggesting that
hypoxia can also lead to release the antiangiogenic factors
from tumor cells. Nevertheless, there is little understanding
of how EMAP II functions at acidic pH after hypoxia in the
tumor tissue, although the antiangiogenic function of EMAP
II in the cell culture system at neutral pH has been studied
intensively. Moreover, the antiangiogenic activity of EMAP
II is in contradiction to the fact that acidic tumor tissue
under hypoxia needs more blood vessels to enhance blood
supply.
In this study, we investigated the regulation of heparin or
HS in the interaction between EMAP II and -ATP synthase.
Accidentally, we found that the interaction between EMAP II
and -ATP synthase was inhibited by heparinized serum.
Basic amino acid clusters, which may serve as a binding site
for heparin, were predicted from the amino acid sequence of
both of EMAP II and -ATP synthase, suggesting that the
interaction between EMAP II and -ATP synthase could be
modulated by heparin or HS. The binding assay indicated
that heparin could bind with both EMAP II and -ATP syn-
thase. Interestingly, low concentrations of heparin and acidic
pH increased the interaction between EMAP II--ATP syn-
thase, whereas excess heparin at neutral pH inhibited it.
Binding of EMAP II to ECs was also increased at acidic pH,
which was mainly ascribed to the binding of EMAP II to HS.
Furthermore, -ATP synthase could interact with HS as well
as EMAP II on the cell surface, suggesting the possibility
that a tertiary complex of HS-EMAP II--ATP synthase
might be formed at acidic pH. Finally, we describe a role for
HS in the function of EMAP II through -ATP synthase of
ECs at acidic pH.
Materials and Methods
Cell Culture. HepG2, Chinese hamster ovary (CHO)-K1, and
Jurkat T cells were obtained from the American Type Culture Col-
lection (Manassas, VA). HepG2 and Jurkat T cells were cultured in
RPMI 1640 medium supplemented with 10% fetal bovine serum and
1% penicillin/streptomycin (all from Cambrex Bio Science Walkers-
ville, Inc., Walkersville, MD) at 37°C in 5% CO2. CHO-K1 was
cultured in Dulbecco’s modified Eagle’s medium (Cambrex Bio Sci-
ence Walkersville, Inc.) supplemented with 10% fetal bovine serum
and 1% penicillin/streptomycin. Bovine aorta endothelial cells
(BAECs) were a gift from Dr. Sunghoon Kim (Seoul National Uni-
versity, Seoul, Korea). BAECs were maintained in Dulbecco’s modi-
fied Eagle’s medium supplemented with 20% fetal bovine serum and
1% penicillin/streptomycin. For experiments, BAECs were used at
confluence from passages 5 to 9.
Expression and Purification of Recombinant Protein. Ex-
pression and purification of recombinant EMAP II from pET28a-
EMAP II have been described previously (Chang et al., 2002).
pET28a-EMAP II was used as a template to introduce single to triple
point mutations by appropriate pairs of overlapping oligonucleotides
by polymerase chain reaction. The primer pairs were 5-catatgtcta-
agccaatagatgtttcc-3 and 5-gagataatactcccatcatctttgcagg-3 for
Em73 (71–73 aa: KMR3KMM) and 5-aaggagctgaatcctatgaagatgatt-
tgggagcag-3 and 5-ctcgagttatttgattccactgttgctcatggt-3 for Em121
(121–123 aa: KKK3MKM). The double mutant form of EMAP II,
Em73,121 (71–73 aa: KMR3KMM and 121–123 aa: KKK3MKM),
was also constructed. The primer pair used for the preparation
of mutant -ATP synthase, ATPs-m167 (167–171 aa: KTRRR3
MTRMM), was 5-tacgcgtcatggaaccaattggac-3 and 5-aacgcgtatgat-
ggttggtctgaaagcccccggtatc-3. pET24d--ATP synthase (a generous
gift from Dr. S. Pizzo, Duke University Medical Center, Durham,
NC; Moser et al., 1999), pET28a-Em73, pET28a-Em121, pET28a-
Em73,121, and pET28a-ATPs-m167 were introduced into compe-
tent Escherichia coli BL21 (DE3) and induced with isopropyl -D-
thiogalactoside. The His-tagged proteins of -ATP synthase, Em73,
Em121, Em73,121, and ATPs-m167 were purified using nickel-
affinity chromatography following the manufacturer’s instructions
(Invitrogen, Carlsbad, CA).
ELISA. Modulation of the interaction between EMAP II and
-ATP synthase by heparin was determined by ELISA. In brief,
96-well microtiter plates (Maxisorp F96; Nalge Nunc, Naperville, IL)
were coated with 200 ng/well recombinant -ATP synthase in 50 mM
carbonate buffer, pH 9.6, and incubated overnight at 4°C. After
washing with PBS, the remaining sites were blocked with PBS
containing 1% BSA (Sigma-Aldrich, St. Louis, MO) for 30 min at
room temperature. For inhibition studies, coated -ATP synthase
was preincubated with serially diluted sera or increasing amounts of
heparin (Invitrogen) for 30 min before adding EMAP II, and then
incubated with 250 ng/ml biotin-conjugated EMAP II for 2 h at room
temperature. For cross-binding by heparin, coated -ATP synthase
was preincubated with or without 250 mU/ml heparin, and after
washing out to remove unbound heparin, incubated with biotin-
conjugated EMAP II. For heparin binding studies, each of native and
mutant forms of EMAP II or -ATP synthase was coated with 200
ng/well in 50 mM carbonate buffer, pH 9.6. After blocking with 1%
BSA/PBS, serially diluted biotin-conjugated heparin-BSA was added
and incubated for 1 h at room temperature. The plates were washed
and incubated with alkaline phosphatase-conjugated streptavidin
(Pierce Chemical, Rockford, IL) diluted in PBS/0.1% BSA/Tween 20
(1:2000) for 1 h at room temperature. The plates were washed, and
then 100 l of phosphatase substrate (p-nitrophenyl-phosphate in a
carbonate buffer, pH 9.6) was added to each well. The absorbance
was read at 405 nm (reference wavelength 490 nm) using an Emax
microplate reader (Molecular Devices, Sunnyvale, CA).
Flow Cytometry. BAECs were harvested, washed with ice-cold
PBS, and then incubated with 20 g/ml fluorescein isothiocyanate
(FITC)-conjugated EMAP II or Em73,121 for 1 h at 4°C in PBS
containing 1% BSA and 0.1% sodium azide, pH 7.5 or 6.5. Binding
inhibition experiments by heparin were performed by staining with
20 g/ml FITC-conjugated EMAP II after preincubation with various
concentrations of heparin. For double inhibition by heparin and
-ATP synthase, BAEC, HepG2, Jurkat T, and CHO-K1 cells were
preincubated with both and either 10 U/ml heparin or 80 g/ml
soluble recombinant -ATP synthase and then stained with 20 g/ml
FITC-conjugated EMAP II. After the last wash, the cells were resus-
pended in 200 l of PBS and analyzed using a FACSCalibur flow
cytometer (BD Biosciences, San Jose, CA) and CellQuest Pro soft-
ware (BD Biosciences).
Immunoprecipitation. BAECs were incubated with 20 g/ml
EMAP II for 1 h at 4°C under either pH 7.5 or 6.5 medium, washed
with ice-cold PBS, and cell lysates were prepared using CytoBuster
protein extraction reagent (Novagen, San Diego, CA) containing
protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN). For
coimmunoprecipitation, 500 l of lysate of BAECs was incubated
with agarose-conjugated anti-syndecan-1 antibody (Santa Cruz Bio-
technology, Inc., Santa Cruz, CA) for binding to HS and Ni-agarose
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(Invitrogen) for binding to His-tagged EMAP II for 3 h at 4°C. The
beads were then washed extensively with binding buffer (10 mM
Tris-HCl, pH 8.0, 140 mM NaCl, and 0.025% NaN3) containing 0.1%
Triton X-100, resuspended in SDS-polyacrylamide gel electrophore-
sis buffer, and boiled for 5 min. The supernatants were resolved on
12% SDS-polyacrylamide gel, transferred to a polyvinylidene diflu-
oride membrane, and blocked with 5% skim milk in TBST (10 mM
Tris, pH 7.5, 0.15 M NaCl, and 0.1% Tween) for 1 h. Precipitation of
HS and EMAP II was confirmed by probing with anti-syndecan-1
antibody (Santa Cruz Biotechnology, Inc.) and anti-His-tag antibody
(QIAGEN, Valencia, CA) in the TBST containing 0.1% skim milk,
respectively. For the coprecipitation of -ATP synthase, transferred
membrane was incubated with polyclonal -ATP synthase antibody
(Chang et al., 2002) in the TBST containing 0.1% skim milk. After
being washed four times with TBST, they were incubated with horse-
radish peroxidase-conjugated secondary antibodies for 1 h and de-
veloped on film using an enhanced chemiluminescence substrate
(Santa Cruz Biotechnology, Inc.), according to the manufacturer’s
instructions.
Cell Proliferation Assay. BAECs were seeded into 96-well tis-
sue culture plates at a density of 10,000 cells/well in the complete
medium and then changed with the medium depleted of fetal bovine
serum overnight to allow the cells to become quiescent. BAECs were
treated with various concentrations (12.5–100 nM) of EMAP II or
mutant forms of it diluted with a fresh medium containing 20% fetal
bovine serum, pH 7.5 or 6.5. Cell density was measured after 24 h by
using the CellTiter 96 aqueous assay kit (Promega, Madison, WI).
The absorbance of formazan was quantitated on an Emax microplate
reader at a wavelength of 490 nm according to the manufacturer’s
instructions. The absorbance values were used to calculate the per-
centage of inhibition of the cell proliferation. For inhibition of EMAP
II function by excess heparin, BAECs were treated with 50 nM
EMAP II in the presence of excess heparin (12.5–400 U/ml) at pH 7.5
or 6.5. For HS depletion, BAECs were treated with 0.5 U/ml hepa-
rinase I (Sigma-Aldrich) and heparinase III (Sigma-Aldrich) for 2 h
at 37°C. After extensive washing with PBS, BAECs were treated
with 50 nM EMAP II at pH 7.5 or 6.5.
Statistics. Comparative statistical analyses were performed us-
ing Student’s t test. Each experiment was repeated at least twice.
Results
Exogenous Heparin Inhibits the Interaction be-
tween EMAP II and -ATP Synthase. Our previous study
demonstrated that EMAP II interacted with -ATP synthase
in the specific manner (Chang et al., 2002). In this study, we
surprisingly found that naive murine and human serum as
well as antiserum against -ATP synthase inhibited the in-
teraction of EMAP II with -ATP synthase (Fig. 1A). Inhib-
itory capacity of naive serum was slightly lower than but
comparable with antiserum against -ATP synthase. More-
over, 50% inhibition was achieved in the highly diluted sam-
ple of naive serum (1:12,800), suggesting that an unknown
factor inhibiting the interaction might be present in these
sera. Therefore, we wished to identify the factor inhibiting
the interaction between EMAP II and -ATP synthase. Sev-
eral angiogenic factors and inhibitors are known to bind with
heparin, which is closely associated with angiogenesis and
antiangiogenesis. On the other hand, blood samples are gen-
erally treated with excess heparin to prevent clotting. To
check heparin as a candidate for the inhibition factor, we
tested whether the interaction between EMAP II and -ATP
synthase was inhibited by nonheparinized serum. The inhi-
bition capacity of nonheparinized serum was significantly
decreased (Fig. 1B). Moreover, exogenous heparin could com-
pletely inhibit the interaction at high concentrations (1000,
50, and 62.5 mU/ml) (Fig. 1C). These results suggested that
the inhibition factor of EMAP II--ATP synthase interaction
could be heparin.
Heparin Binds with EMAP II and -ATP Synthase.
Modulation of EMAP II--ATP synthase interaction by hep-
arin suggested the possibility that heparin could bind with
EMAP II and/or -ATP synthase. To test this, we evaluated
the binding of heparin to EMAP II or -ATP synthase. Hep-
arin bound with both EMAP II (Fig. 2A) and -ATP synthase
Fig. 1. Inhibition of the interaction between EMAP II
and -ATP synthase by heparin. Modulation of the
interaction between EMAP II and -ATP synthase by
heparinized sera or exogenous heparin was deter-
mined by ELISA. The coated -ATP synthase was
preincubated with serially diluted sera (A and B) or
increasing amounts of heparin (C) for 30 min before
adding of 250 ng/ml biotin-conjugated EMAP II. The
bound EMAP II was probed with alkaline phospha-
tase-conjugated streptavidin and then detected with
phosphatase substrate. The data are shown as a per-
centage of inhibition calculated from the absorbance
at 405 nm. A, naive murine and human sera as well
as murine antiserum could inhibit the interaction
between EMAP II and -ATP synthase. B, inhibition
by heparin-free serum was reduced compared with
heparinized serum. C, excess heparin could inhibit
the interaction between EMAP II and -ATP syn-
thase in a concentration-dependent manner.
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(Fig. 2C) in a concentration-dependent manner and the bind-
ing was saturable at high concentration. When heparin bind-
ing motif was searched from the amino acid sequences of
EMAP II and -ATP synthase, EMAP II and -ATP synthase
were found to contain two and one basic heparin binding
motif, respectively. In subsequent studies, we performed site-
directed mutagenesis changing critical arginine or lysine res-
idues to methionine residues. To map binding sites, we
mutated the putative heparin binding motif of EMAP II
gene either individually or in double combination and ex-
pressed recombinant mutant forms of EMAP II, including
Em73 (71–73 aa: KMR3KMM), Em121 (121–123 aa:
KKK3MKM), and Em73,121 (71–73 aa: KMR3KMM and
121–123 aa: KKK3MKM). Binding of heparin with Em73
and Em121 was partially reduced, whereas binding with
Em73,121 was abolished (Fig. 2A). However, binding capac-
ities of mutant EMAP II to -ATP synthase were similar to
that of native EMAP II (Fig. 2B). Likewise, heparin binding
to the mutant form of -ATP synthase, ATPs-m167 (167–
171 aa: KTRRR3MTRMM), was dramatically reduced (Fig.
2C), although the interaction between ATPs-m167 and
EMAP II (Fig. 2D) was not changed. These results suggested
that heparin binding motifs of EMAP II and -ATP synthase
were critical for heparin binding but not for the interaction
between EMAP II and -ATP synthase. Together, the data
demonstrated that heparin could regulate the interaction
between EMAP II and -ATP synthase by binding with both
EMAP II and -ATP synthase.
Interaction between EMAP II and -ATP Synthase
Increases by Heparin and Acidic pH. Hypoxia is a potent
inducer of the release and processing of biologically active
EMAP II from tumor cells (Barnett et al., 2000). Hypoxic
conditions lead to reduced extracellular pH. Several reports
proposed that the interaction of heparin and heparin binding
molecules such as VEGF could be increased at acidic pH
(Goerges and Nugent, 2003). Thus, we first considered the
possibility that heparin binding to EMAP II or -ATP syn-
thase could be altered by pH. As expected based on previous
reports, heparin binding to each of EMAP II and -ATP
synthase also increased at pH 6.5 (Fig. 3, A and B). In
contrast with the inhibition of the -ATP synthase-EMAP II
interaction by excess heparin (Fig. 1C), removal of unbound
heparin to -ATP synthase before adding EMAP II could
increase EMAP II--ATP synthase interaction, and the in-
creased binding was potentiated by acidic pH (Fig. 4A). Con-
sistent with this observation, low concentrations (4, 1, and
0.25 mU/ml) of heparin slightly enhanced the interaction
between EMAP II and -ATP synthase (Fig. 1C). However,
the interaction between Em73,121 and ATPs-m167 was
increased neither by acidic pH nor by the addition of heparin
(Fig. 4B). These results suggested that the interaction be-
tween EMAP II and -ATP synthase could be further en-
hanced by cross-linking of heparin under acidic conditions.
Binding of EMAP II to ECs Increases at Acidic pH.
ECs constitutively express HS as well as -ATP synthase on
the cell surface (Moser et al., 1999; Goerges and Nugent,
2003). Because HS can be a cellular counterpart of heparin,
we evaluated whether EMAP II interacted with HS as well as
-ATP synthase on the surface of ECs. The binding of EMAP
II to ECs increased as the extracellular pH was decreased
from 7.5 to 6.5 (Fig. 5A), but OVA protein used as a control
did not bind to ECs at any pH (data not shown). Unlabeled
EMAP II competed with FITC-labeled EMAP II for the bind-
ing to ECs at pH 6.5, suggesting that EMAP II binding to ECs
at pH 6.5 was specific (Fig. 5B). In addition, the enhanced
EMAP II binding at pH 6.5 was dramatically inhibited by
excess heparin (10 and 100 U/ml) in a concentration-depen-
dent manner, whereas the binding at pH 7.5 was not inhib-
ited by heparin (Fig. 5C). Furthermore, binding of Em73,121
to EC at pH 6.5 was decreased compared with that of EMAP
II, although there was no difference at pH 7.5 (Fig. 5D).
These results suggested that the enhanced binding of EMAP
II to ECs at acidic pH was caused mainly by the binding of
EMAP II to HS. It has been shown that HepG2 cells as well
Fig. 2. Heparin binding motif of EMAP II and -ATP
synthase. Recombinant proteins mutated in the putative
heparin binding motif, Em73, Em121, Em73,121, and
ATPs-m167 were expressed. These mutant forms were
tested for the binding activity to heparin (A and C) and
their counterpart protein (B and D). To test the heparin
binding activity of mutated sites, native and mutant forms
of EMAP II (A) or -ATP synthase (C) were incubated with
serially diluted biotin-conjugated heparin-BSA (1–4000
ng/ml). B, to check the binding activities of mutant forms of
EMAP II to -ATP synthase, various concentrations of
biotin-conjugated naive or mutant EMAP II proteins were
incubated with coated -ATP synthase. D, to check the
binding activity of the mutant form of -ATP synthase to
EMAP II, coated naive or mutant forms of -ATP synthase
were incubated with various concentrations of biotin-con-
jugated EMAP II. The binding of biotin-conjugated hepa-
rin-BSA or biotin-conjugated EMAP II were detected with
alkaline phosphatase-conjugated streptavidin.
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as BAECs express constitutively both HS and /-ATP syn-
thase at the cell surface (Martinez et al., 2003). In BAECs
and HepG2 cells, EMAP II binding at pH 6.5 was signifi-
cantly blocked by soluble -ATP synthase or heparin and
more dramatically by both of them. Similar results could be
obtained in Jurkat T cells having -ATP synthase in the lipid
rafts (von Haller et al., 2001) and in CHO-K1 cells for which
the presence of surface ATP synthase complex is unknown
(Fig. 5E).
To further define the binding of EMAP II to ECs, binding
curves were obtained from flow cytometry data using FITC-
conjugated EMAP II (Fig. 6A). After subtraction of the non-
specific interactions, binding was found to be concentration-
dependent and saturable at high concentrations. Scatchard
plot analysis at pH 7.5 showed a single binding slope with a
binding affinity Kd of 245 nM (Bmax of 28.79) that was prob-
ably involved in the EMAP II binding to surface -ATP syn-
thase. Unexpectedly, Scatchard plot analysis at pH 6.5 also
showed a single binding slope with a lower binding affinity
Kd of 2469 nM (Bmax of 1493), although we hypothesized that
BAECs had two binding sites for EMAP II, including HS and
-ATP synthase at acidic conditions. On the basis of these
data, we predicted that HS--ATP synthase complex might
be a binding receptor for EMAP II under acidic conditions.
On the other hand, HS might be a major binding site with
low-binding affinity to EMAP II at pH 6.5, whereas -ATP
synthase, a high-affinity receptor, might play a minor role for
EMAP II binding because of very low frequency of -ATP
synthase compared with abundant HS in the surface of ECs.
To exploit the interaction among them in the EC surface, we
performed immunoprecipitation against HS and EMAP II
from BAEC lysates after binding of EMAP II at pH 7.5 or 6.5
(Fig. 6B). The immunoprecipitation of HS was independent of
pH. More EMAP II was precipitated at pH 6.5 than at pH 7.5,
supporting that binding of EMAP II to BAECs increased at
pH 6.5. To check the coprecipitation of -ATP synthase,
Western blotting of each precipitant using polyclonal anti--
ATP synthase antibody was performed. -ATP synthase was
coprecipitated with EMAP II at pH 7.5, consistent with our
previous report (Chang et al., 2002), and more coprecipita-
tion was shown at pH 6.5. Furthermore, -ATP synthase was
coprecipitated with HS at pH 6.5 but not at pH 7.5. These
data suggested that the EMAP II--ATP synthase interac-
tion and the HS--ATP synthase interaction were increased
at acidic pH. In addition, these data suggested the possibility
that ternary complexes of HS-EMAP II--ATP synthase
might be formed at acidic pH. Together, these results sup-
ported our hypothesis that after EMAP II was secreted from
the cells under oxidative stress, it could interact with both
HS and -ATP synthase on ECs in acidic environments after
hypoxia.
HS Can Regulate the Function of EMAP II on ECs at
Acidic pH. To define the role of HS for the antiangiogen-
esis at an acidic condition, we tested EC proliferation
using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium assay. BAECs could grow fairly well at pH 6.5, and
the proliferation of BAECs at pH 6.5 was similar to that at
pH 7.5 (Fig. 7A). Percentage of inhibition of BAEC prolif-
eration by EMAP II was significantly increased at pH 6.5
(Fig. 7B). However, inhibition by Em73,121 was not in-
creased at pH 6.5 compared with that at pH 7.5 (Fig. 7C).
In addition, the inhibitory capacity of Em73,121 was sig-
nificantly decreased compared with that of EMAP II at pH
6.5, although inhibitory capacities between EMAP II and
Fig. 3. Increased binding of heparin at acidic pH. To
test whether heparin binding to EMAP II or -ATP
synthase can be affected by pH, we performed the hep-
arin binding assay at two different pHs using ELISA.
Heparin binding to -ATP synthase (A) or EMAP II (B)
was increased at pH 6.5 compared with heparin binding
at pH 7.5. , p  0.01; , p  0.001 (Student’s t test).
Fig. 4. Increased binding between EMAP II and
-ATP synthase by heparin and acidic pH. To test
whether the interaction between EMAP II and
-ATP synthase may be affected by cross-linking of
heparin, we performed the binding assay using
ELISA. A, for cross-binding by heparin, coated
-ATP synthase were preincubated with (F, Œ) or
without 250 mU/ml heparin (E, ‚) at pH 7.5 (circles)
or pH 6.5 (triangles) and after washing out to re-
move unbound heparin, incubated with biotin-con-
jugated EMAP II. The -ATP synthase-EMAP II
binding was enhanced by both of heparin and acidic
pH. B, interaction between Em73,121 and mutant
-ATPs-m167 was increased by neither acidic pH
nor heparin.
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Em73,121 had little difference at pH 7.5. On the basis of
these data, we predicted that the enhanced effect of EMAP
II at pH 6.5 could be ascribed to the enhanced binding of
EMAP II to ECs, which resulted from the enhanced inter-
action among EMAP II-HS--ATP synthase under acidic
conditions. To evaluate which of two heparin binding mo-
tifs was more important for the enhanced effect at acidic
pH, the inhibition of BAEC proliferation by a mutant se-
ries of EMAP II was analyzed. The inhibition by Em73 was
slightly but not significantly reduced compared with
EMAP II, whereas inhibition by Em121 and Em73,121 was
significantly reduced (Fig. 7D). Thus, the data suggested
that the KKK (121–123 aa)-HS binding region was more
important for the function of EMAP II at acidic pH. To
confirm whether the enhanced effect of EMAP II resulted
from the regulation of HS at acidic pH, we tested whether
exogenous heparin could inhibit the enhanced effect of
EMAP II at pH 6.5. Although high concentrations of hep-
arin were required, the inhibition of BAEC proliferation by
EMAP II was abrogated by heparin at pH 6.5 (Fig. 7E). In
contrast, exogenous heparin had no effect at pH 7.5. To
provide further evidence, we tested antiproliferative ef-
fects of EMAP II after HS depletion. The enhanced effects
of EMAP II on ECs at pH 6.5 were significantly inhibited
by heparinase I and heparinase III treatment (Fig. 7F).
These data suggested that HS could modulate the function
of EMAP II at acidic pH. Collectively, these results sug-
gested that the effect of EMAP II on ECs could increase as
Fig. 5. Increased EMAP II binding to BAECs
at acidic pH. EMAP II binding to ECs was
measured using flow cytometry. A, EMAP II
binding to BAECs was dramatically in-
creased at pH 6.5. B, increased EMAP II
binding was inhibited by unlabeled EMAP
II. C, EMAP II binding to BAECs was inhib-
ited in presence of excess heparin in a con-
centration-dependent manner at pH 6.5,
whereas the binding was independent of
heparin at pH 7.5. D, Em73,121 binding to
BAECs was reduced more than that of
EMAP II binding at pH 6.5, although the
binding of EMAP II and Em73,121 at pH 7.5
was similar. E, for double inhibition by hep-
arin and -ATP synthase, BAEC, HepG2,
Jurkat T, and CHO-K1 cells were preincu-
bated with both and either 10 U/ml heparin
or 80 g/ml soluble -ATP synthase and then
stained with 20 g/ml FITC-conjugated
EMAP II. All BAEC, HepG2, Jurkat T, and
CHO-K1 cells were inhibited by both of hep-
arin and -ATP synthase at pH 6.5.
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the extracellular pH decreased, and this was ascribable to
the interaction of EMAP II with HS at an acidic condition.
Discussion
In ECs, surface -ATP synthase can interact with EMAP II
(Chang et al., 2002) or angiostatin (Moser et al., 1999), and
their interactions lead to EC apoptosis. In this study, we first
reported that the interaction between EMAP II and -ATP
synthase could be regulated by heparin or HS. Each of EMAP
II and -ATP synthase could interact with heparin and was
found to contain the heparin binding sites evidenced by anal-
ysis using the site-directed mutant forms (Fig. 2). One of the
best studied model systems for protein-HS interactions is the
FGF family, and recent observations have demonstrated that
FGF-FGFR-heparan sulfate-like glycosaminoglycans ternary
complexes can be formed because HS also interacts directly
with FGFRs as well as FGF, and these interactions potenti-
ate FGF binding to FGFR (Yayon et al., 1991; Fannon et al.,
2000). Likewise, it has been shown that VEGF binding to
VEGF receptors is dependent on HS (Tessler et al., 1994).
However, several antiangiogenic factors are known to bind to
heparin, but their biological meanings are less well estab-
lished. Although endostatin, the well known antiangiogenic
factor, is extensively studied regarding the interaction be-
tween endostatin and HS and endostatin inhibits angiogen-
esis by binding to HS as a low-affinity coreceptor (Ricard-
Blum et al., 2004), the importance of heparin binding for the
antiangiogenic activity of endostatin also remains to be elu-
cidated. Our data demonstrated that HS as well as heparin
at the cellular level could interact directly with both EMAP II
and -ATP synthase and enhance the interaction between
EMAP II and -ATP synthase. On the basis of these data, we
proposed the possibility that the interaction among them
might form the HS-EMAP II--ATP synthase complexes on
the EC surface under acidic conditions and that this complex
via cross-interaction of HS could enhance EMAP II binding to
its functional receptor, -ATP synthase. This idea was sup-
ported because the interaction between EMAP II and -ATP
synthase was increased by a low dose of heparin at the
molecular level. Thus, together, the data clearly showed that
HS in the ECs could potentiate the binding of EMAP II to
-ATP synthase and the effects of EMAP II on ECs. On the
other hand, p43, the precursor of EMAP II, also contains
many putative heparin binding motifs in the N-terminal
region as well as EMAP II region. Thus, it may be possible
that p43 also interacts with HS and the binding of p43 to ECs
increases by p43-HS interaction.
Our study suggested that HS was involved in the func-
tion of EMAP II on ECs at acidic pH but not at neutral pH.
Low extracellular pH is a common feature of solid tumors
(Tannock, 1972). ECs are exposed to this environment
while undergoing angiogenesis under many pathological
and physiological conditions. However, it has been shown
that ECs are protected from apoptosis in an acidic envi-
ronment (D’Arcangelo et al., 2000). On the other hand, it
has also been found that the antiangiogenic activity of
angiostatin on ECs is enhanced in culture when the micro-
environmental extracellular pH is reduced to levels similar
to that of many tumors (Wahl and Grant, 2002). These
results provide evidence for the importance of pH in the
growth of ECs. Hypoxia in the growing tumor, which re-
sults in the acidic microenvironment, is a major factor not
only for releasing angiogenic factors such as VEGF but
also for releasing EMAP II from tumor cells. ECs in the
tumor vasculature can be exposed to EMAP II released
from tumor cells under the hypoxic and acidic microenvi-
Fig. 6. Binding analysis of EMAP II to
ECs and HS--ATP synthase interaction
on the EC surface. A, binding assay was
performed in BAECs, with various con-
centrations of FITC-conjugated EMAP II
at pH 7.5 and 6.5 using flow cytometry.
The insets show Scatchard plots of the
specific binding. B, for coimmunoprecipi-
tation, lysates of BAECs that were incu-
bated with 20 g/ml EMAP II for 1 h at
4°C at either pH 7.5 or 6.5 were precipi-
tated with agarose-conjugated anti-syn-
decan-1antibody for binding to HS or Ni-
agarose for binding to His-tagged EMAP
II. Precipitation of HS and EMAP II were
confirmed by probing with anti-synde-
can-1 antibody and anti-His-tag antibody,
respectively. The coprecipitation of -ATP
synthase was detected by Western blot-
ting using polyclonal -ATP synthase an-
tibody.
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ronment. In our results, the inhibitory effects of BAEC
proliferation by EMAP II were increased at acidic pH.
These results were supported by the previous report that
EMAP II-induced apoptosis of ECs was enhanced in the
hypoxic condition (Schwarz et al., 1999). Together, the
antiangiogenic activity of EMAP II might be enhanced by
hypoxia. However, this is contradictory to the fact that
hypoxia induces the expression of angiogenic factors and
inhibits EC apoptosis because tumors under hypoxia need
more blood vessels to enhance blood supply. In this regard,
we have speculated why the tumor cells release EMAP II
under hypoxic conditions.
In general, HS is expressed in most tissues and is a
major component of cell surfaces and the ECM (Bernfield
et al., 1999). HS can act as a suppressor or activator of
angiogenesis (Nugent and Iozzo, 2000; Esko and Lindahl,
2001; Turnbull et al., 2001). HS on the EC surface may
localize heparin binding proteins, whereas HS in other
cells or the ECM may act as a site for heparin binding
protein storage, sequestering proteins from their receptors
on EC surface. The enhanced inhibitory effects of EMAP II
by HS at an acidic condition were obtained from in vitro
EC culture system. In the tumor tissue, these acidic loca-
tions would not be adjacent to the existing vasculature;
hence, there would be little ECs in the immediate environ-
ment of the secreted EMAP II. Thus, EMAP II released
under a hypoxic condition binds to HS in the nonendothe-
lial cells or ECM and can be sequestered. When tissues are
sufficient for blood supply by angiogenesis and pH in-
creases from acidic to neutral, the sequestered EMAP II
can be released from the ECM and exert its effects on its
target cells. Therefore, the function of EMAP II under
physiological conditions may be regulated via modulation
of the binding affinity between HS-EMAP II.
Our data demonstrated that the interaction of EMAP II
and -ATP synthase to HS could be regulated by extracel-
lular pH and modulate the antiangiogenic effects of EMAP
II. EMAP II also has biological activity in T lymphocytes
Fig. 7. Regulation of EMAP II-
induced antiangiogenesis by HS
at acidic pH. The proliferation of
BAECs was measured by 3-(4,
5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium assay. A, growth of
BAECs at pH 7.5 and pH 6.5. The
data are expressed as a percentage
of proliferation  S.E. with re-
spect to the cell at pH 7.5. B,
BAECs were treated with EMAP
II at either pH 7.5 (black) or pH
6.5 (white). Percentage of inhibi-
tion of BAEC proliferation by
EMAP II was significantly in-
creased at the pH 6.5. C, BAECs
were treated with EMAP II or
Em73,121 at either pH 7.5 or 6.5.
Inhibitory effects of BAEC prolif-
eration by Em73,121 were not in-
creased at pH 6.5. D, BAECs were
treated with naive or mutant
forms of EMAP II at pH 6.5. The
proliferation inhibition by Em121
and Em73,121 was significantly
reduced compared with EMAP II.
In A to C, the data are expressed
as a percentage of inhibition 
S.E. of cell proliferation with re-
spect to nontreated cells. E,
BAECs were treated with 50 nM
EMAP II in the presence of excess
heparin at pH 7.5 or 6.5. Data are
expressed as percentage of inhibi-
tion  S.E. of EMAP II-induced
antiproliferative effects by hepa-
rin with respect to 50 nM EMAP
II-treated and nontreated cells. F,
BAECs were treated with hepari-
nase I  III, washed extensively
with PBS, and then incubated
with 50 nM EMAP II. The data are
expressed as a percentage of inhi-
bition  S.E. of cell proliferation
with respect to nontreated cells. ,
p  0.01; , p  0.001; , p 
0.0001 (Student’s t test).
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and monocytes as well as ECs (Murray et al., 2004). T cells
(von Haller et al., 2001) and monocytes (Li et al., 2003)
have been found to express both of HS and ATP synthase.
The investigation regarding the involvement of HS and
-ATP synthase in T cell apoptosis or monocyte chemotaxis
will be interesting. Moreover, recent results suggest that
cell surface HS is not uniformly distributed but instead
seems to be localized to cholesterol-rich lipid raft domains
(Tkachenko and Simons, 2002), and HS can modulate
FGF-2 binding through a lipid raft-mediated mechanism
(Chu et al., 2004). In addition, endostatin associates with
lipid rafts, and heparinase treatment of cells prevents the
recruitment of endostatin to the lipid rafts (Wickström et
al., 2003). Because ATP synthase in T cells and monocytes
has been found to be present in lipid rafts, it remains to be
investigated whether HS can regulate the lipid raft local-
ization of ATP synthase.
In fact, the differences in the antiangiogenic effects of
EMAP II between pH 7.5 and 6.5 (Fig. 7) were relatively
small, even though they are statistically significant. How-
ever, physiological pH under hypoxic conditions can be more
acidic. A previous report showed that the extracellular space
within malignant tissues has been measured at as low as pH
5.8 (Wike-Hooley et al., 1984). We observed that the binding
of EMAP II could be increased when pH decreased below pH
6.0 (data not shown). Therefore, the antiangiogenic activity
of EMAP II might be more potent under physiological hy-
poxia than normal oxidative conditions. In addition, blood
vessels in tumor tissues are under balance between various
angiogenic and antiangiogenic factors. The regulation mech-
anisms of the vascular system are regarded as a very com-
plicated. Furthermore, the relationship between the antian-
giogenesis and hypoxia (acidic pH) remain to be clarified. We
suggest that our results could be a clue to unveiling the
puzzling network.
In the current study, we proposed the regulation of EMAP
II-induced antiangiogenesis by HS at acidic pH. In ECs, HS
may regulate the function of EMAP II released from the
tumor cell in hypoxic conditions (acidic condition). These
observations provide a biological mechanism that plausibly
explains the regulation mechanism of antiangiogenesis via
HS and pH. Furthermore, these findings provide novel in-
sight into understanding the complex network of tumor cells
and vasculature system.
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